Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy Hazel

Nurse Practitioner Canton, OH Nurse Practitioner

NPI 1568468965 CMS profile 11025182

4650 Hills And Dales Rd Nw, Canton, OH 44708

Open in the dashboard

General payments

$62,728

485 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Hazel of Canton, OH is reported in the CMS Open Payments database as having received $62,728 across 485 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,048 111
2024 General $19,078 132
2023 General $12,523 94
2022 General $13,426 76
2021 General $7,654 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Hazel
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Amy Hazel were reported at $10,048. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Amy Hazel Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $7,654 $135 $40–$426 $132
2022 $13,426 $152 $48–$470 $149
2023 $12,523 $166 $54–$529 $160
2024 $19,078 $173 $55–$556 $164
2025 $10,048 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Fresenius USA Marketing, Inc. $32,203 86 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $7,556 54 payments
  3. Akebia Therapeutics Inc $7,178 43 payments
  4. Novartis Pharmaceuticals Corporation $5,205 48 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $3,636 11 payments
  6. AstraZeneca Pharmaceuticals LP $921 31 payments
  7. Amgen Inc. $900 33 payments
  8. Otsuka America Pharmaceutical, Inc. $822 29 payments
  9. OPKO Pharmaceuticals, LLC $727 15 payments
  10. Daiichi Sankyo Inc. $658 31 payments
  11. Other $2,922 104 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Honoraria $18,500 11 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,968 15 payments
  3. Food and Beverage $11,442 395 payments
  4. Travel and Lodging $8,267 37 payments
  5. Consulting Fee $6,738 3 payments
  6. Education $813 24 payments
Products named General payments · program years 2021–2025
  1. Velphoro $32,184 84 payments
  2. Kerendia $7,556 54 payments
  3. Vafseo $6,996 34 payments
  4. Fabhalta $4,239 27 payments
  5. TOLVAPTAN $3,433 4 payments
  6. JYNARQUE $882 32 payments
  7. RAYALDEE $727 15 payments
  8. INJECTAFER $658 31 payments
  9. FARXIGA $517 20 payments
  10. Parsabiv $439 16 payments
  11. Other $4,376 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

2,159

Median for Nurse Practitioner: 389

Drug cost

$196,866

Median for Nurse Practitioner: $21,885

Branded share of claims

15.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 52 $50,331
Velphoro Sucroferric Oxyhydroxide Brand 12 $37,680
Auryxia Ferric Citrate Brand 24 $29,116
Prosol Parenteral Amino Acid 20% No.1 Brand 111 $18,635
Sevelamer Carbonate Generic 103 $13,759
Lokelma Sodium Zirconium Cyclosilicate Brand 16 $12,479
Kerendia Finerenone Brand 17 $10,636
Calcitriol Generic 179 $3,252
Bumetanide Generic 60 $2,332
Hydralazine Hcl Generic 132 $1,781

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Velphoro
  • Fresenius USA Marketing, Inc. $12,143
$12,143 12 —
Fabhalta
  • Novartis Pharmaceuticals Corporation $3,962
$3,962 — —
JYNARQUE
  • Otsuka America Pharmaceutical, Inc. $238
$238 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $220
$220 17 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $218
$218 52 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

485 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record